Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
161.60    1.60 (1.00%)
Bid:
159.20
Ask:
160.80
Spread: 1.60 (1.005%)
Market Cap: £274.83m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

AGM Trading Update

23 Nov 2020 07:00

RNS Number : 0909G
McBride PLC
23 November 2020
 

23 November 2020

 

 

McBride plc

 

AGM Trading Update

 

 

McBride (the "Group"), the leading European manufacturer and supplier of Contract Manufactured and Private Label products for the domestic household and professional cleaning/hygiene markets, provides the following trading update ahead of its 2020 Annual General Meeting to be held later today.

 

The early part of the financial year has experienced demand patterns similar to those seen in the COVID-19 affected last four months of the year ended 30 June 2020. Changes to consumers' behaviours seen in the earlier stages of the pandemic have largely continued with strong demand for bleach, auto-dish and surface cleaning products offset by lower demand for laundry products. Both the Aerosols and Asia units have experienced strong revenue growth. Total revenues are broadly flat after the first four months and are expected to show modest growth for the first half of the year. 

 

Earnings growth is expected to be weighted to the first half of the year, reflecting weak comparatives in the prior period and improved margins from efficiencies, lower operating costs as well as lower input costs for certain raw material and packaging items. Whilst all factories are currently operating as normal and the supply chain for inbound and outbound materials is functioning well, the Board's full year view is cautious in light of the potential for future operational challenges resulting from Covid-19, the uncertainty arising from the Brexit process and the unknown impact on consumer demand from renewed lockdowns in our principal markets. Our full year outlook on trading therefore remains unchanged, with our current expectations for a modest improvement in yearonyear profitability.

 

The Group's interim results will be announced on 23 February 2021 and will be followed by a separate presentation providing an update on Programme Compass, McBride's new strategic initiative, along with details on our new product-led divisional strategies.

 

 

 

For further information please contact:

 

 

 

McBride plc

 

Chris Smith, Chief Executive Officer

0161 203 7401

Clive Jennings, Interim Chief Finance Officer

0161 203 7401

 

 

FTI Consulting LLP

020 3727 1017

Ed Bridges, Nick Hasell

 

 

 

Note: This announcement contains inside formation which is disclosed in accordance with the Market Abuse Regulations which came into effect on 3 July 2016. 

 

-Ends-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEAXFAALAEFFA
Date   Source Headline
1st Dec 20257:00 amRNSLaunch of share buyback programme
28th Nov 20256:29 pmRNSRedemption of B Shares and Total Voting Rights
27th Nov 202512:27 pmRNSHolding(s) in Company
25th Nov 20257:00 amRNSHolding(s) in Company
20th Nov 20254:40 pmRNSAGM Statement
20th Nov 20257:00 amRNSAGM Trading Update and Share Buyback
18th Nov 20259:42 amRNSHolding(s) in Company
31st Oct 20257:00 amRNSTotal Voting Rights
27th Oct 20257:00 amRNSHolding(s) in Company
23rd Oct 20256:15 pmRNSDirector/PDMR Shareholding
22nd Oct 20257:00 amRNSApplication for Additional Listing of Shares
17th Oct 20256:23 pmRNSDirector/PDMR Shareholding
2nd Oct 20257:00 amRNSAnnual Financial Report
24th Sep 20257:00 amRNSRedemption of B Shares
19th Sep 20257:00 amRNSDirector/PDMR Shareholding
18th Sep 20259:04 amRNSEx-dividend date - Correction
17th Sep 20257:00 amRNSFinal Results
5th Sep 20257:00 amRNS-RInvestor Webinar on 18 September 2025
16th Jul 20257:00 amRNSFull Year Trading Update
16th Jun 20257:00 amRNSDirector/PDMR Shareholding
10th Jun 20257:00 amRNSHolding(s) in Company
29th May 20253:19 pmRNSHolding(s) in Company
23rd May 20251:42 pmRNSHolding(s) in Company
19th May 20257:00 amRNSHolding(s) in Company
12th May 20257:00 amRNSHolding(s) in Company
6th May 20257:00 amRNSHolding(s) in Company
29th Apr 20257:00 amRNSHolding(s) in Company
22nd Apr 20257:00 amRNSHolding(s) in Company
8th Apr 20257:00 amRNSHolding(s) in Company
28th Feb 20255:00 pmRNSHolding(s) in Company
25th Feb 20257:00 amRNSHalf-year Report
18th Feb 20256:15 pmRNSHolding(s) in Company
11th Feb 20254:40 pmRNSHolding(s) in Company
17th Jan 20257:00 amRNSTrading Statement
29th Nov 20247:00 amRNSSuccessful Completion of Refinancing
18th Nov 20241:10 pmRNSDirector/PDMR Shareholding
18th Nov 20241:09 pmRNSDirector/PDMR Shareholding
15th Nov 20241:10 pmRNSDirector/PDMR Shareholding
12th Nov 20246:36 pmRNSResult of Annual General Meeting
12th Nov 20247:00 amRNSAGM Trading Update
6th Nov 20243:53 pmRNSDirector/PDMR Shareholding
31st Oct 20247:00 amRNSDirector/PDMR Shareholding
25th Oct 20243:48 pmRNSDirector/PDMR Shareholding
8th Oct 20246:25 pmRNSDirector/PDMR Shareholding
7th Oct 20247:00 amRNSAnnual Financial Report
1st Oct 20245:30 pmRNSDirector/PDMR Shareholding
26th Sep 20247:00 amRNSDirector/PDMR Shareholding
24th Sep 20243:38 pmRNSDirector/PDMR Shareholding
20th Sep 20245:17 pmRNSDirector/PDMR Shareholding
19th Sep 20247:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.